


EVALUATION OF THE EFFICACY AND SAFETY OF MIFAMURTIDE IN OSTEOGENIC SARCOMA TREATMENT IN PAEDIATRIC PATIENTS



DGI-034



S. Berisa¹, E. Lacalle¹, M.E. Carrasco¹, F. Marcotegui¹, S. Martínez², M. Gutiérrez¹, M. Castresana¹, M. Elviro¹, E. Pellejero¹
¹Hospital B Complejo Hospitalario de Navarra, Hospital Pharmacy, Pamplona, Spain
²Hospital San Pedro, Hospital Pharmacy, Logroño, Spain

BACKGROUND

Osteosarcoma is a common bone tumor, with an incidence of 0.2 to 3/100 000, is an orphan disease.

PURPOSE

➤ Mifamurtide has managed to increase survival without increasing side effects. We try to evaluate the safety and efficacy of mifamurtide in two paediatric patients diagnosed of osteogenic sarcoma.

MATERIALS AND METHODS


Prospective study of two paediatric patients

Diagnostic: Osteogenic sarcoma

Therapeutic indications of mifamurtide

In children, adolescents and young adults for the treatment of high-grade resectable non-metastatic osteosarcoma after surgical resection. It is used in combination with post-operative chemotherapy.

Protocol administered: **SEOP-SO-2010** of the Spanish Society of Paediatric Oncology (during 37 weeks)



Monitoring patients

During the chemotherapy

Weekly: we assist to the oncology sessions and we track them

After chemotherapy

Through the electronic clinical history

RESULTS

	PATIENT 1	PATIENT 2
AGE START Chemotherapy	12	15
START DATE	July 2010	November 2010

SIDE EFFECTS	SOLUTIONS
Flu-reaction (1 st dose)	Following dose administered with premedication (acetaminophen and dexchlorpheniramine)
Anemia and Thrombocytopenia	Human stimulating factors and platelet concentrates
Vomits	Aprepitant

• From the chemotherapy finished to the actually: Both patients are in **complete remission**, 10 and 13 months later

CONCLUSIONS

- Protocol SEOP plus mifamurtide has achieved a complete remission in both cases.
- The use of mifamurtide can be considered safe and it hasn't increased side effects, we observed only attributed to mifamurtide, a flu syndrome resolved with premedication.
- The effectiveness of mifamurtide in osteogenic sarcoma treatment can not be completed due to the small sample size.